Antimicrobial membrane activity.
Host-defense peptides that disrupt microbial membranes and steer immune responses.
Antimicrobial peptides are an ancient arm of innate immunity, found across essentially all multicellular life. They work on a physical principle rather than a receptor one. The peptides are cationic, carrying a net positive charge, and amphipathic, meaning they have distinct hydrophobic and hydrophilic faces. Bacterial membranes are rich in anionic phospholipids and lipopolysaccharide, giving them a strongly negative surface charge, whereas mammalian cell membranes present mostly neutral phospholipids on their outer leaflet and contain cholesterol. The charge difference is what provides selectivity. On contact with a microbial membrane the peptide binds electrostatically, then inserts its hydrophobic face into the lipid bilayer. At sufficient local concentration this produces either detergent-like disruption of the membrane or organised pores, and the cell loses its ability to maintain an electrochemical gradient. Because the target is the membrane's basic physical composition rather than a specific protein, resistance is harder for bacteria to acquire than resistance to conventional antibiotics, though it is not impossible. Activity extends across Gram-positive and Gram-negative bacteria, some fungi, and enveloped viruses, and these peptides can also neutralise lipopolysaccharide and disrupt biofilms. Direct killing is only part of the story, and arguably not the most important part at physiological concentrations. The human cathelicidin in this group is strongly immunomodulatory: it is chemotactic for neutrophils, monocytes, and T cells, acting partly through a formyl peptide receptor, and it promotes angiogenesis, keratinocyte migration, and wound closure. Its expression is induced by vitamin D, which is one of the more concrete mechanistic links between vitamin D status and innate immune function. The same properties that make these peptides useful also make them difficult drugs. Selectivity for microbial over host membranes is relative rather than absolute, so systemic administration risks damaging host cells, and the peptides are rapidly degraded by proteases and inactivated by physiological salt concentrations and serum proteins. This is the central reason that decades of interest have produced few approved systemic antimicrobial peptides. Honest summary: the membrane-disruption mechanism is well established biophysically and is not in dispute. The immunomodulatory roles are also well documented in laboratory systems. What has not been established is that administering these peptides to people produces clinical benefit, and this cathelicidin has also been implicated in driving inflammation in certain skin conditions, meaning more is not straightforwardly better.
Peptides acting through this pathway.
FAQ.
What does antimicrobial membrane activity do?
Antimicrobial peptides are an ancient arm of innate immunity, found across essentially all multicellular life. They work on a physical principle rather than a receptor one. The peptides are cationic, carrying a net positive charge, and amphipathic, meaning they have distinct hydrophobic and hydrophilic faces. Bacterial membranes are rich in anionic phospholipids and lipopolysaccharide, giving them a strongly negative surface charge, whereas mammalian cell membranes present mostly neutral phospholipids on their outer leaflet and contain cholesterol. The charge difference is what provides selectivity. On contact with a microbial membrane the peptide binds electrostatically, then inserts its hydrophobic face into the lipid bilayer. At sufficient local concentration this produces either detergent-like disruption of the membrane or organised pores, and the cell loses its ability to maintain an electrochemical gradient. Because the target is the membrane's basic physical composition rather than a specific protein, resistance is harder for bacteria to acquire than resistance to conventional antibiotics, though it is not impossible. Activity extends across Gram-positive and Gram-negative bacteria, some fungi, and enveloped viruses, and these peptides can also neutralise lipopolysaccharide and disrupt biofilms. Direct killing is only part of the story, and arguably not the most important part at physiological concentrations. The human cathelicidin in this group is strongly immunomodulatory: it is chemotactic for neutrophils, monocytes, and T cells, acting partly through a formyl peptide receptor, and it promotes angiogenesis, keratinocyte migration, and wound closure. Its expression is induced by vitamin D, which is one of the more concrete mechanistic links between vitamin D status and innate immune function. The same properties that make these peptides useful also make them difficult drugs. Selectivity for microbial over host membranes is relative rather than absolute, so systemic administration risks damaging host cells, and the peptides are rapidly degraded by proteases and inactivated by physiological salt concentrations and serum proteins. This is the central reason that decades of interest have produced few approved systemic antimicrobial peptides. Honest summary: the membrane-disruption mechanism is well established biophysically and is not in dispute. The immunomodulatory roles are also well documented in laboratory systems. What has not been established is that administering these peptides to people produces clinical benefit, and this cathelicidin has also been implicated in driving inflammation in certain skin conditions, meaning more is not straightforwardly better.
Which peptides act through antimicrobial membrane activity?
LL-37. They share this pathway but differ in evidence, approval, and safety.
Does this mechanism prove a peptide works?
No. Mechanistic plausibility is not proof of clinical benefit. A plausible pathway is a reason to study a compound, not evidence that it works in humans.